Tranexamic acid
- Generic Name
- Tranexamic acid
- Brand Names
- Cyklokapron, Lysteda
- Drug Type
- Small Molecule
- Chemical Formula
- C8H15NO2
- CAS Number
- 1197-18-8
- Unique Ingredient Identifier
- 6T84R30KC1
- Background
Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.
It was first patented in 1957 and received its initial US approval in 1986.
- Indication
Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.
- Associated Conditions
- Bleeding, Heavy Menstrual Bleeding, Hereditary Angioedema (HAE)
- Associated Therapies
- -
Tranexamic Acid in Total Knee Replacement
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Democritus University of Thrace
- Target Recruit Count
- 180
- Registration Number
- NCT03656445
Efficacy of Tranexamic Acid in Foot and Ankle Surgeries
- Conditions
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 100
- Registration Number
- NCT03653429
- Locations
- 🇺🇸
Ichan School of Medicine, New York, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Reducing Hemarthrosis in ACL Reconstruction With BTB Autograft by the Administration of Intravenous TXA
- Conditions
- Interventions
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 110
- Registration Number
- NCT03631355
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
Tranexamic Acid in Pregnancies With Vaginal Bleeding
- Conditions
- Interventions
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Hawler Medical University
- Target Recruit Count
- 139
- Registration Number
- NCT03632824
- Locations
- 🇮🇶
Hawler Medical University, Erbil, Kurdistan Region, Iraq
Tranexamic Acid in Major Orthopedic Surgery: Comparison of 3 Dosage Regimen
- Conditions
- Interventions
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- CUF Santarém Hospital
- Target Recruit Count
- 210
- Registration Number
- NCT03573245
Tranexamic Acid for Prevention of Postpartum Haemorrhage: a Dose-finding Study
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Mount Sinai Hospital, Canada
- Target Recruit Count
- 24
- Registration Number
- NCT03565276
- Locations
- 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients
- Conditions
- Interventions
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 50
- Registration Number
- NCT03552705
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
PeriOperative ISchemic Evaluation-3 Trial
- First Posted Date
- 2018-04-23
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 9535
- Registration Number
- NCT03505723
- Locations
- 🇨🇦
Sherbrooke, Sherbrooke, Quebec, Canada
🇦🇺Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇧🇷Hospital do Coracao de Pocos de Caldas, Poços De Caldas, Minas Gerais, Brazil
World Maternal Antifibrinolytic Trial_2
- Conditions
- Interventions
- First Posted Date
- 2018-03-23
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 15068
- Registration Number
- NCT03475342
- Locations
- 🇳🇬
Ilorin General Hospital, Ilorin, Nigeria
🇵🇰Chandka SMBBMU Sheikh Zaid Woman Hospital Unit 1, Larkana, Pakistan
🇳🇬Adeoyo Maternity Hospital, Ibadan, Nigeria
California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Arrowhead Regional Medical Center
- Target Recruit Count
- 200
- Registration Number
- NCT03469947
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.